- Home
- AAL vs BBIO Comparison
AAL vs BBIO Comparison
Compare AAL & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAL
- BBIO
- Stock Information
- Founded
- AAL 1930
- BBIO 2015
- Country
- AAL United States
- BBIO United States
- Employees
- AAL 132100
- BBIO N/A
- Industry
- AAL Air Freight/Delivery Services
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- AAL Consumer Discretionary
- BBIO Health Care
- Exchange
- AAL Nasdaq
- BBIO Nasdaq
- Market Cap
- AAL 7.0B
- BBIO 6.7B
- IPO Year
- AAL N/A
- BBIO 2019
- Fundamental
- Price
- AAL $10.56
- BBIO $34.57
- Analyst Decision
- AAL Buy
- BBIO Strong Buy
- Analyst Count
- AAL 17
- BBIO 11
- Target Price
- AAL $17.76
- BBIO $52.90
- AVG Volume (30 Days)
- AAL 65.0M
- BBIO 2.8M
- Earning Date
- AAL 04-24-2025
- BBIO 05-01-2025
- Dividend Yield
- AAL N/A
- BBIO N/A
- EPS Growth
- AAL 3.11
- BBIO N/A
- EPS
- AAL 1.24
- BBIO N/A
- Revenue
- AAL $54,211,000,000.00
- BBIO $221,902,000.00
- Revenue This Year
- AAL $6.94
- BBIO $6.31
- Revenue Next Year
- AAL $4.91
- BBIO $131.17
- P/E Ratio
- AAL $8.60
- BBIO N/A
- Revenue Growth
- AAL 2.70
- BBIO 2285.27
- 52 Week Low
- AAL $9.07
- BBIO $21.62
- 52 Week High
- AAL $19.10
- BBIO $39.47
- Technical
- Relative Strength Index (RSI)
- AAL 28.11
- BBIO 51.35
- Support Level
- AAL $10.97
- BBIO $35.77
- Resistance Level
- AAL $12.07
- BBIO $37.06
- Average True Range (ATR)
- AAL 0.45
- BBIO 1.40
- MACD
- AAL 0.08
- BBIO 0.18
- Stochastic Oscillator
- AAL 24.88
- BBIO 47.67
About AAL American Airlines Group Inc.
American Airlines is the world's largest airline by aircraft, capacity, and scheduled revenue passenger miles. Its major US hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. It generates over 30% of US airline revenue connecting Latin America with destinations in the United States. After completing a major fleet renewal, the company has the youngest fleet of US legacy carriers.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.